EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Bone histomorphometric evaluation of daily and intermittent oral ibandronate in postmenopausal osteoporosis



Bone histomorphometric evaluation of daily and intermittent oral ibandronate in postmenopausal osteoporosis



Calcified Tissue International 72(4): 402, April




(PDF emailed within 1 workday: $29.90)

Accession: 034500113

Download citation: RISBibTeXText



Related references

Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study. Osteoporosis International 15(3): 231-237, 2004

Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: A review of three Phase II studies. Clinical Therapeutics 25(1): 19-34, January, 2003

Daily oral ibandronate prevents bone loss in postmenopausal women without osteoporosis. Journal of Bone & Mineral Research 17(Suppl 1): S157, September, 2002

Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis. Journal of Bone and Mineral Research 19(1): 11-18, 2004

Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis. Journal of Bone and Mineral Research 16(10): 1871-1878, 2001

Intermittent intravenous ibandronate injections are more effective than daily oral ibandronate for improving bone density at the hip: DIVA 2-year analysis. 2006

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. Journal of Bone and Mineral Research 19(8): 1241-1249, 2004

Response to once-monthly and daily oral ibandronate in women with postmenopausal osteoporosis: 2-year findings from mobile. 2006

Association between pharmacokinetics of oral ibandronate and clinical response in bone mass and bone turnover in women with postmenopausal osteoporosis. Bone (New York) 30(1): 320-324, January, 2002

Effects of intermittent intravenous ibandronate injections on bone quality and micro-architecture in women with postmenopausal osteoporosis: the DIVA study. Bone 46(3): 660-665, 2010

Similar improvements in hip bone mineral density with monthly oral ibandronate (150mg) versus weekly oral alendronate (70mg) in postmenopausal osteoporosis. 2007

Once-monthly oral ibandronate improves biomechanical determinants of bone strength in women with postmenopausal osteoporosis. Journal of Clinical Endocrinology and Metabolism 94(1): 171-180, 2008

Non-vertebral fracture benefit from oral ibandronate administered daily or with a unique drug-free interval Results from a pivotal phase III study in postmenopausal osteoporosis. Journal of Bone & Mineral Research 17(Suppl 1): S134, September, 2002

Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporosis International 15(10): 792-798, 2004

Impact of oral ibandronate 15mg once monthly on bone structure and density in postmenopausal osteoporosis or osteopenia derived from in vivo ?CT. 2011